v3.26.1
Condensed Statements of Changes in Shareholders' Deficit - USD ($)
Common Stock [Member]
Archimedes Tech SPAC Partners II Co
Common Stock [Member]
Additional Paid-in Capital [Member]
Archimedes Tech SPAC Partners II Co
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Archimedes Tech SPAC Partners II Co
Retained Earnings [Member]
Archimedes Tech SPAC Partners II Co
Total
Balance (in shares) at Dec. 31, 2024 5,750,000              
Balance at Dec. 31, 2024 $ 575   $ 24,425   $ (78,700)   $ (53,700)  
Balance (in shares) at Jun. 06, 2024 0              
Balance at Jun. 06, 2024 $ 0   0   0   0  
Sale of 840,0000 private placement units (in shares) 5,750,000              
Sale of 840,0000 private placement units $ 575   24,425   0   25,000  
Net loss [1] $ 0   0   (78,700)   (78,700)  
Balance (in shares) at Dec. 31, 2024 5,750,000              
Balance at Dec. 31, 2024 $ 575   24,425   (78,700)   $ (53,700)  
Sale of 840,0000 private placement units (in shares) 840,000           8,400,000  
Sale of 840,0000 private placement units $ 84   8,399,916       $ 8,400,000  
Net loss         1,159,223   1,159,223  
Fair value of Public Warrants at issuance     1,725,000       1,725,000  
Allocated value of transaction costs to warrants and private placement units 0   (117,194)   0   (117,194)  
Accretion of ordinary shares subject to possible redemption amount $ 0   (10,032,147)   (7,207,063)   (17,239,210)  
Balance (in shares) at Mar. 31, 2025 6,590,000              
Balance at Mar. 31, 2025 $ (659)   0   6,126,540   6,125,881  
Balance (in shares) at Dec. 31, 2024 5,750,000              
Balance at Dec. 31, 2024 $ 575   24,425   (78,700)   $ (53,700)  
Sale of 840,0000 private placement units (in shares) 840,000           8,400,000  
Sale of 840,0000 private placement units $ 84   8,399,916   0   $ 8,400,000  
Net loss 0 [1]   0   7,986,738   7,986,738  
Fair value of Public Warrants at issuance 0   1,725,000   0   1,725,000  
Allocated value of transaction costs to warrants and private placement units 0 [1]   (117,194)   0   (117,194)  
Accretion of ordinary shares subject to possible redemption amount $ 0   (10,032,147)   (14,612,148)   (24,644,295)  
Balance (in shares) at Dec. 31, 2025 6,590,000 100           100
Balance at Dec. 31, 2025 $ 659   0 $ 10 (6,704,110) $ (659) (6,703,451) $ (659)
Balance (in shares) at Dec. 03, 2025   0            
Balance at Dec. 03, 2025   $ 0   0   0   0
Sale of 840,0000 private placement units (in shares)   100            
Sale of 840,0000 private placement units       10        
Net loss           (659)   $ (659)
Balance (in shares) at Dec. 31, 2025 6,590,000 100           100
Balance at Dec. 31, 2025 $ 659   $ 0 10 (6,704,110) (659) (6,703,451) $ (659)
Net loss         1,704,803 (37,269) 1,704,803 $ (37,269)
Accretion of ordinary shares subject to possible redemption amount         (2,141,962)   (2,141,962)  
Balance (in shares) at Mar. 31, 2026 6,590,000             100
Balance at Mar. 31, 2026 $ 659     $ 10 $ (7,141,269) $ (37,928) $ (7,140,610) $ (37,928)
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.